Cleveland BioLabs, Inc. (NASDAQ:CBLI)

Cleveland Biolabs has a history of being less than forthright about their prospects, and also of collusion with skeevy stock promoters like M.E.Garza. Nevertheless, I'll bestow a green thumb on them at this low market cap as I expect they will provide positive spin on an upcoming meeting with the FDA regarding the BLA for Entolimod. If the stock does bump on such guidance, expect a large dilutive financing faster than you can call BS.

I hope my gut-feeling is right - the upcoming ASCO will raise the interest in cancer-fighting companies...

up up & away

Cleveland is way undervalued at this point, 2 drug applications for CBLB502 and a BARDA deal on the way... this will double in weeks and be a great buy and hold stock for years to come.

Company located in the new Medical Corridor in Buffalo, NY.
Yesterday, the increase of +62.99% is just the tip of the iceberg.
This stock will continue to outperform the S&P500

big pop big drop

Bounce coming. Recent news was not the death knell that was touted.

Overreaction to BARDA decision looks like a buying opportunity.

Price action indicates upward trend in monthly, weekly and daily time frame. Volume spike + Chaikin Oscillator indicates bullish trend.

Stock fell off in July. Since then, heavy insider purchases and a thumbs up from zzlangerhan.

Asymmetric risk/reward. BARDA grant would further legitimize science behind 502, leading to domestic & international government orders. Total market size should be $300-$500 million for the drug, and CBLI should get good margins on a large order.

A golfing buddy of mine told me his son had recently bought 50,000 shares of a bioteck co and asked me to look at it for him. I rarely buy stocks under $ 10 and almost never one that dosn't pay at least a 4 % div.
I suggested to my buddie that his son should have a winner and if he could afford a little risk he should jump on it also. I then bouhgt 5000 shrs and several options.
Todays news granting "orphan status" from tha FDA intiated this post. If this drug comes anywhere near doing what their studies show, it couyld be a triple bagger very quickly. I bought between 6.00 and 6.30 it croosed 9.95 this am.

Won a DoD contract for $45 million. Lots of news out on this one in the past few weeks including a patent being granted.

If all goes well with CBLI's research, we can hope to see a drug that increases human resistance to radiation. In my opinion, a truly groundbreaking discovery with an obtainable goal in sight, and their first round of testing going well only adds to my optimism.

Read the Bios of their researchers, you will be impressed. In this world the projects they are working on are timely and amazing.

Expecting 200M+ dod contract to develope ARS drug in October.

Way too high of price/sales and price/book

The company focuses on radiation drug discovery. The drugs they are working on target only cancer cells and don't harm normal tissues. Their inital target is to protect humans from radiation as a result of a terrorist attack or nuclear accident.

Cleveland Biolabs (CBL) is a biotechnology research and development company, which develops drugs offering protection from radiation and cancer. CBL is engaged in the development of small molecule drugs and biologics focusing on two therapeutic directions, which includes development of drugs that protect normal tissues from the damaging effects of ionizing radiation and chemotherapy (protectans), and development of anti-cancer drugs for regulating cell death (curaxins).

Financially company has been running in losses from past three-four years. For the nine months ended in 2006, company’s revenues increased 93% to $1.5 million predominantly driven by increase in government grants. But it had a net loss totaled of $4.3 million, which was owing to an increase in selling, general and administrative expenses. Also due to creating and improving the infrastructure of the company and higher research & development expenses incurred for internal projects.

CBL intends to respond to a Request for Proposal (RFP) recently issued by the Department of Defense (DoD) for the Advanced Development of Medical Radiation Countermeasures to treat gastrointestinal effects of acute radiation syndrome. More recently company completed a $30 million private placement. This will provide them with two years of working capital and enable them to fulfill the requirements of the DoD's RFP as well as move forward with the development of radiation protection, cancer treatment and stem cell proliferation. But the above would gain only in the long run.

Looking at all the above factors and consequently due to increasing expenses in research & development every year coupled with deteriorating financials, the scrip is expected to enter a bearish phase.